[go: up one dir, main page]

WO2009041700A1 - Composition pharmaceutique - Google Patents

Composition pharmaceutique Download PDF

Info

Publication number
WO2009041700A1
WO2009041700A1 PCT/JP2008/067693 JP2008067693W WO2009041700A1 WO 2009041700 A1 WO2009041700 A1 WO 2009041700A1 JP 2008067693 W JP2008067693 W JP 2008067693W WO 2009041700 A1 WO2009041700 A1 WO 2009041700A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
stretch
pharmaceutical composition
composition
nerve
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/067693
Other languages
English (en)
Japanese (ja)
Inventor
Manabu Nozaki
Shigeki Sawamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kobayashi Pharmaceutical Co Ltd
Original Assignee
Kobayashi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kobayashi Pharmaceutical Co Ltd filed Critical Kobayashi Pharmaceutical Co Ltd
Publication of WO2009041700A1 publication Critical patent/WO2009041700A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition qui peut inhiber l'activité d'inhibition de l'étirement nerveux d'un composé 1 contenu dans cette composition ; et une composition capable de favoriser l'étirement nerveux, qui peut favoriser, de manière significative, l'étirement d'une cellule nerveuse. L'invention concerne ainsi une composition pharmaceutique caractérisée en ce qu'elle renferme un composé 1 et un composé 2 ; et une composition destinée à favoriser l'étirement nerveux, qui est caractérisée en ce qu'elle renferme au moins un composé 1 et un composé 2 et en ce qu'elle comprend en outre un composé 3.
PCT/JP2008/067693 2007-09-28 2008-09-29 Composition pharmaceutique Ceased WO2009041700A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007256016A JP5376785B2 (ja) 2007-09-28 2007-09-28 医薬組成物
JP2007-256016 2007-09-28

Publications (1)

Publication Number Publication Date
WO2009041700A1 true WO2009041700A1 (fr) 2009-04-02

Family

ID=40511578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/067693 Ceased WO2009041700A1 (fr) 2007-09-28 2008-09-29 Composition pharmaceutique

Country Status (2)

Country Link
JP (1) JP5376785B2 (fr)
WO (1) WO2009041700A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579584A (zh) * 2011-01-06 2012-07-18 赵能 一种疏通经络治理面瘫的保健丸

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5376786B2 (ja) * 2007-09-28 2013-12-25 小林製薬株式会社 神経細胞賦活組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504104A (ja) * 1996-11-06 2001-03-27 ブリストル―マイヤーズ・スクイブ・カンパニー アルツハイマー病の治療法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3768800A (en) * 1999-03-26 2000-10-16 Emil H. Franssen Treatment of brain changes with myelin protective agents
JP5376786B2 (ja) * 2007-09-28 2013-12-25 小林製薬株式会社 神経細胞賦活組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001504104A (ja) * 1996-11-06 2001-03-27 ブリストル―マイヤーズ・スクイブ・カンパニー アルツハイマー病の治療法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SWEENEY, C.J. ET AL.: "Two drug interaction studies evaluating the pharmacokinetics and toxicity of pemetrexed when coadministered with aspirin or Ibuprofen in patients with advanced cancer", CLIN CANCER RES, vol. 12, no. 2, 2006, pages 536 - 542 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102579584A (zh) * 2011-01-06 2012-07-18 赵能 一种疏通经络治理面瘫的保健丸

Also Published As

Publication number Publication date
JP5376785B2 (ja) 2013-12-25
JP2009084207A (ja) 2009-04-23

Similar Documents

Publication Publication Date Title
WO2008106128A3 (fr) Inhibiteurs d'urée et de carbamate de 11b-hydroxystéroïde déshydrogénase 1 cycliques
WO2008024497A3 (fr) INHIBITEURS DE LA 11β-HYDROXYSTÉROÏDE DÉSHYDROGÉNASE DE TYPE 1
WO2009075835A8 (fr) Inhibiteurs cycliques d'urée de la 11-hydroxystéroïde déhydrogénase 1
WO2010108074A3 (fr) Inhibiteurs de pi3 kinase
TN2012000248A1 (en) Novel spiropiperidine compounds
WO2011014795A3 (fr) Composés et compositions pouvant servir d'inhibiteurs de la kinase syk
MX2012004420A (es) Compuestos de espiropiperidino y uso farmaceutico de los mismos para tratar diabetes.
WO2010003133A3 (fr) Modulateurs de cdk
WO2008103470A3 (fr) Composés létaux dépendants du signal de ras oncogénique
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
IL198979A (en) Enzyme inhibitors diacylglycerol o-acetyltransferase type 1
WO2011033265A8 (fr) Composés pharmaceutiques
WO2008070268A3 (fr) Compositions pharmaceutiques
PH12013500879A1 (en) Crystalline forms of hydrochloride salt of (4a-r,9a-s) -1- (1h - benzoimidazole- 5 -carbonyl) -2, 3, 4, 4a, 9, 9a - hexahydro -1h- indeno [2, 1 -b] pyridine- 6 -carbonitrile and their use as hsd 1 inhibitors
WO2009038412A3 (fr) Composés inhibiteurs de la béta-sécrétase
WO2011047055A3 (fr) Nouveaux inhibiteurs de mek, utiles dans le traitement des maladies
WO2008129501A3 (fr) Compositions pharmaceutiques de duloxetine
MY165041A (en) Composition for improving brain function and method for improving brain function
WO2010123959A3 (fr) Antagonistes ccr3 d'arylsulfonamides 2,5-disubstitués
WO2011088160A3 (fr) Nouveaux inhibiteurs de cyp17
WO2010062506A3 (fr) Inhibiteurs de cyp17 décahydro-1h-indénoquinolinone et décahydro-3h-cyclopentaphénanthridinone
WO2009129208A3 (fr) Compositions et procédés permettant d'induire une réponse au stress du réticulum endoplasmique
WO2010072770A3 (fr) Analogues de griséofulvine pour le traitement du cancer par inhibition de l'agrégat centrosomial
WO2009065090A3 (fr) Compositions pharmaceutiques pour le traitement d'affections sensibles à une inhibition du protéasome
GEP20125570B (en) Use of indazolemethoxyalkanoic acid for reducing levels of triglycerides, cholesterol and glucose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08834472

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08834472

Country of ref document: EP

Kind code of ref document: A1